NO2576524T3 - - Google Patents
Info
- Publication number
- NO2576524T3 NO2576524T3 NO11787250A NO11787250A NO2576524T3 NO 2576524 T3 NO2576524 T3 NO 2576524T3 NO 11787250 A NO11787250 A NO 11787250A NO 11787250 A NO11787250 A NO 11787250A NO 2576524 T3 NO2576524 T3 NO 2576524T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34855410P | 2010-05-26 | 2010-05-26 | |
| PCT/US2011/037752 WO2011149945A1 (en) | 2010-05-26 | 2011-05-24 | Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2576524T3 true NO2576524T3 (de) | 2018-03-24 |
Family
ID=45004334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO11787250A NO2576524T3 (de) | 2010-05-26 | 2011-05-24 |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US9359313B2 (de) |
| EP (1) | EP2576524B1 (de) |
| JP (1) | JP5902676B2 (de) |
| KR (2) | KR101878252B1 (de) |
| CN (1) | CN102906077B (de) |
| AU (1) | AU2011258460B2 (de) |
| BR (1) | BR112012029844A2 (de) |
| CA (1) | CA2799591C (de) |
| CO (1) | CO6640324A2 (de) |
| CY (1) | CY1119850T1 (de) |
| DK (1) | DK2576524T3 (de) |
| EA (1) | EA032085B1 (de) |
| ES (1) | ES2655396T3 (de) |
| HK (1) | HK1181044A1 (de) |
| HR (1) | HRP20180113T1 (de) |
| HU (1) | HUE036009T2 (de) |
| IL (1) | IL223137A0 (de) |
| LT (1) | LT2576524T (de) |
| ME (1) | ME03007B (de) |
| MX (1) | MX347372B (de) |
| NO (1) | NO2576524T3 (de) |
| NZ (1) | NZ603614A (de) |
| PE (1) | PE20130275A1 (de) |
| PL (1) | PL2576524T3 (de) |
| PT (1) | PT2576524T (de) |
| RS (1) | RS56761B1 (de) |
| SG (1) | SG185660A1 (de) |
| SI (1) | SI2576524T1 (de) |
| TW (1) | TWI508723B (de) |
| WO (1) | WO2011149945A1 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS56761B1 (sr) | 2010-05-26 | 2018-04-30 | Vtv Therapeutics Llc | Upotreba metformina u kombinaciji sa aktivatorom glukokinaze i kompozicije koje sadrže metformin i aktivator glukokinaze |
| CA2872021C (en) * | 2012-05-17 | 2022-08-16 | Transtech Pharma, Llc | Glucokinase activator compositions for the treatment of diabetes |
| WO2014137797A2 (en) * | 2013-03-04 | 2014-09-12 | Transtech Pharma, Llc | Stable glucokinase activator compositions |
| KR20150126362A (ko) * | 2013-03-04 | 2015-11-11 | 브이티브이엑스 홀딩스 아이 엘엘씨 | 글루코키나제 활성화제를 포함하는 고체 조성물 및 그것의 제조 및 사용 방법 |
| CN110167542A (zh) * | 2016-11-09 | 2019-08-23 | 诺沃梅迪科斯有限公司 | 1,1-二甲双胍的亚硝酸盐、药物组合物和使用方法 |
| KR102695126B1 (ko) * | 2018-05-31 | 2024-08-16 | 후아 메디슨 (상하이) 엘티디. | 글루코키나제 활성화제 및 sglt-2 억제제를 포함하는 약제학적 병용물, 조성물, 및 병용 제제, 및 이의 제조방법 및 용도 |
| EP3806852A1 (de) * | 2018-06-12 | 2021-04-21 | vTv Therapeutics LLC | Therapeutische verwendung von glucokinaseaktivatoren in kombination mit insulin oder insulinanaloga |
| MX2022015524A (es) * | 2020-06-08 | 2023-03-22 | Vtv Therapeutics Llc | Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4-propoxi-c iclohexil)-ureido]-tiazol-5-ilsulfanil}-acetico y uso de las mismas. |
| WO2021252311A1 (en) * | 2020-06-08 | 2021-12-16 | Vtv Therapeutics Llc | Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof |
| CN115073331A (zh) * | 2021-03-15 | 2022-09-20 | 中国医学科学院药物研究所 | 二甲双胍肉桂酸盐一水合物及制备方法和其组合物与用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT323195B (de) * | 1973-03-16 | 1975-06-25 | Hurka Wilhelm | Verfahren zur herstellung neuer salze von biguaniden |
| FR2243684B1 (de) * | 1973-09-19 | 1977-01-28 | Semb | |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4356108A (en) | 1979-12-20 | 1982-10-26 | The Mead Corporation | Encapsulation process |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| KR101116627B1 (ko) | 2002-06-27 | 2012-10-09 | 노보 노르디스크 에이/에스 | 치료제로서 아릴 카르보닐 유도체 |
| ITRM20030053A1 (it) * | 2003-02-10 | 2004-08-11 | Sigma Tau Ind Farmaceuti | Associazione di farmaci antidiabetici. |
| AU2003269484A1 (en) * | 2003-09-11 | 2005-03-29 | Biocon Limited | Salt of atorvastatin with metformin |
| PT1723128E (pt) * | 2004-01-06 | 2013-02-27 | Novo Nordisk As | Heteroaril-ureias e o seu uso como activadores da glicoquinase |
| JP2008515818A (ja) * | 2004-10-07 | 2008-05-15 | ステム セル セラピューティクス コーポレイション | 妊娠に関連する化合物の投与による多能性幹細胞の増殖の刺激 |
| CA2614518A1 (en) * | 2005-07-08 | 2007-01-18 | Novo-Nordisk A/S | Dicycloalkyl urea glucokinase activators |
| WO2007006761A1 (en) * | 2005-07-08 | 2007-01-18 | Novo Nordisk A/S | Dicycloalkylcarbamoyl ureas as glucokinase activators |
| AU2006268589B2 (en) * | 2005-07-14 | 2011-09-29 | Vtv Therapeutics Llc | Urea glucokinase activators |
| JP2010515701A (ja) * | 2007-01-09 | 2010-05-13 | ノボ・ノルデイスク・エー／エス | ウレアグルコキナーゼアクチベーター |
| KR20110018366A (ko) | 2008-05-16 | 2011-02-23 | 다케다 샌디에고, 인코포레이티드 | 글루코키나아제 활성제 |
| KR101190957B1 (ko) | 2009-08-25 | 2012-10-15 | 한올바이오파마주식회사 | 메트포르민 카페익산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제 |
| RS56761B1 (sr) * | 2010-05-26 | 2018-04-30 | Vtv Therapeutics Llc | Upotreba metformina u kombinaciji sa aktivatorom glukokinaze i kompozicije koje sadrže metformin i aktivator glukokinaze |
| CA2872021C (en) | 2012-05-17 | 2022-08-16 | Transtech Pharma, Llc | Glucokinase activator compositions for the treatment of diabetes |
| WO2014137797A2 (en) | 2013-03-04 | 2014-09-12 | Transtech Pharma, Llc | Stable glucokinase activator compositions |
| KR20150126362A (ko) | 2013-03-04 | 2015-11-11 | 브이티브이엑스 홀딩스 아이 엘엘씨 | 글루코키나제 활성화제를 포함하는 고체 조성물 및 그것의 제조 및 사용 방법 |
-
2011
- 2011-05-24 RS RS20180055A patent/RS56761B1/sr unknown
- 2011-05-24 PT PT117872507T patent/PT2576524T/pt unknown
- 2011-05-24 MX MX2012013617A patent/MX347372B/es active IP Right Grant
- 2011-05-24 KR KR1020187006115A patent/KR101878252B1/ko active IP Right Grant
- 2011-05-24 KR KR1020127033687A patent/KR101860120B1/ko active IP Right Grant
- 2011-05-24 HU HUE11787250A patent/HUE036009T2/hu unknown
- 2011-05-24 SG SG2012085080A patent/SG185660A1/en unknown
- 2011-05-24 LT LTEP11787250.7T patent/LT2576524T/lt unknown
- 2011-05-24 EP EP11787250.7A patent/EP2576524B1/de active Active
- 2011-05-24 US US13/114,964 patent/US9359313B2/en active Active
- 2011-05-24 SI SI201131369T patent/SI2576524T1/en unknown
- 2011-05-24 BR BR112012029844A patent/BR112012029844A2/pt not_active IP Right Cessation
- 2011-05-24 NO NO11787250A patent/NO2576524T3/no unknown
- 2011-05-24 PL PL11787250T patent/PL2576524T3/pl unknown
- 2011-05-24 EA EA201201617A patent/EA032085B1/ru not_active IP Right Cessation
- 2011-05-24 PE PE2012002211A patent/PE20130275A1/es not_active Application Discontinuation
- 2011-05-24 ES ES11787250.7T patent/ES2655396T3/es active Active
- 2011-05-24 CA CA2799591A patent/CA2799591C/en active Active
- 2011-05-24 NZ NZ603614A patent/NZ603614A/en not_active IP Right Cessation
- 2011-05-24 AU AU2011258460A patent/AU2011258460B2/en active Active
- 2011-05-24 ME MEP-2018-24A patent/ME03007B/de unknown
- 2011-05-24 WO PCT/US2011/037752 patent/WO2011149945A1/en active Application Filing
- 2011-05-24 CN CN201180025744.3A patent/CN102906077B/zh active Active
- 2011-05-24 DK DK11787250.7T patent/DK2576524T3/en active
- 2011-05-24 JP JP2013512164A patent/JP5902676B2/ja active Active
- 2011-05-25 TW TW100118368A patent/TWI508723B/zh active
-
2012
- 2012-11-19 IL IL223137A patent/IL223137A0/en not_active IP Right Cessation
- 2012-12-21 CO CO12232453A patent/CO6640324A2/es not_active Application Discontinuation
-
2013
- 2013-07-15 HK HK13108290.5A patent/HK1181044A1/xx unknown
-
2016
- 2016-02-11 US US14/988,143 patent/US9855251B2/en active Active
-
2017
- 2017-08-28 US US15/687,824 patent/US10064846B2/en active Active
-
2018
- 2018-01-04 CY CY20181100011T patent/CY1119850T1/el unknown
- 2018-01-22 HR HRP20180113TT patent/HRP20180113T1/hr unknown
- 2018-08-08 US US16/058,512 patent/US10363244B2/en active Active